# ACTengine (NCT03686124)

> ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03686124
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Immatics US, Inc.
- Conditions: Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult; Cancer
- Interventions: IMA203 Product; IMA203 product- flat dose; IMA203CD8 Product; Nivolumab; IMADetect®
- Enrollment: 375
- Primary outcome: Phase 1: Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8
- Primary outcome: Phase 1 and Phase 2: Number and grade of treatment emergent adverse events and adverse events of special interest in subjects treated.
- Primary outcome: Phase 1 and Phase 2: Tumor Response

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=actengine-nct03686124